{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:59:42Z","timestamp":1776754782573,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01914-2","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T08:48:49Z","timestamp":1745398129000},"page":"1296-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pancreatitis associated with BRAF inhibitors: a disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1007","volume":"47","author":[{"given":"Shoujun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huahua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3209-2584","authenticated-orcid":false,"given":"Jiangfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"2","key":"1914_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.11.011","volume":"142","author":"C Hertzman Johansson","year":"2014","unstructured":"Hertzman Johansson C, Egyhazi BS. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142(2):176\u201382. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.011.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"1914_CR2","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel). 2019;11(10):1618. https:\/\/doi.org\/10.3390\/cancers11101618.","journal-title":"Cancers (Basel)"},{"key":"1914_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coph.2015.05.015","volume":"23","author":"W Zhang","year":"2015","unstructured":"Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol. 2015;23:68\u201373. https:\/\/doi.org\/10.1016\/j.coph.2015.05.015.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"1914_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cancers11091388","volume":"11","author":"F Crispo","year":"2019","unstructured":"Crispo F, Notarangelo T, Pietrafesa M, et al. BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel). 2019;11(9):1388. https:\/\/doi.org\/10.3390\/cancers11091388.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1914_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/cancers12061571","volume":"12","author":"J Molina-Cerrillo","year":"2020","unstructured":"Molina-Cerrillo J, San Roman M, Pozas J, et al. BRAF mutated colorectal cancer: new treatment approaches. Cancers (Basel). 2020;12(6):1571. https:\/\/doi.org\/10.3390\/cancers12061571.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1914_CR6","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1002\/cam4.3103","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Nazmun N, Hassan S, et al. BRAF mutation and its inhibitors in sarcoma treatment. Cancer Med. 2020;9(14):4881\u201396. https:\/\/doi.org\/10.1002\/cam4.3103.","journal-title":"Cancer Med"},{"issue":"16","key":"1914_CR7","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-13-0779","volume":"19","author":"AK Salama","year":"2013","unstructured":"Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013;19(16):4326\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0779.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1914_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-021-00827-2","volume":"22","author":"BR Halle","year":"2021","unstructured":"Halle BR, Johnson DB. Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol. 2021;22(4):30. https:\/\/doi.org\/10.1007\/s11864-021-00827-2.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"1914_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(14)70012-9.","journal-title":"Lancet Oncol"},{"issue":"9839","key":"1914_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X.","journal-title":"Lancet"},{"issue":"5","key":"1914_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1914_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2165\/00002018-200831100-00002","volume":"31","author":"AR Balani","year":"2008","unstructured":"Balani AR, Grendell JH. Drug-induced pancreatitis\u202f: incidence, management and prevention. Drug Saf. 2008;31(10):823\u201337. https:\/\/doi.org\/10.2165\/00002018-200831100-00002.","journal-title":"Drug Saf"},{"issue":"4","key":"1914_CR13","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/phar.1208","volume":"33","author":"B Muluneh","year":"2013","unstructured":"Muluneh B, Buie LW, Collichio F. Vemurafenib-associated pancreatitis: case report. Pharmacotherapy. 2013;33(4):e43-44. https:\/\/doi.org\/10.1002\/phar.1208.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1914_CR14","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/MPA.0000000000001704","volume":"50","author":"GJ Ruan","year":"2021","unstructured":"Ruan GJ, Goyal G, Shah MV, et al. Acute pancreatitis from treatment with BRAF inhibitors in Erdheim-Chester disease: a report from 2 tertiary referral centers. Pancreas. 2021;50(1):e6-8. https:\/\/doi.org\/10.1097\/MPA.0000000000001704.","journal-title":"Pancreas"},{"issue":"4","key":"1914_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1914_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10(3):420. https:\/\/doi.org\/10.3390\/healthcare10030420.","journal-title":"Healthcare (Basel)"},{"key":"1914_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13: 862508. https:\/\/doi.org\/10.3389\/fphar.2022.862508.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1914_CR18","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/bcp.16127","volume":"90","author":"ZX Zhao","year":"2024","unstructured":"Zhao ZX, Yang TY, Wang YH, et al. Cardiovascular events of Bruton\u2019s tyrosine kinase inhibitors: a real-world study based on the United States food and drug administration adverse event reporting system database. Br J Clin Pharmacol. 2024;90(9):2166\u201379. https:\/\/doi.org\/10.1111\/bcp.16127.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1914_CR19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.21873\/invivo.13567","volume":"38","author":"K Ohyama","year":"2024","unstructured":"Ohyama K, Iida M, Akiyama S, et al. Time-to-onset analysis of rhabdomyolysis due to different proton pump inhibitors using a pharmacovigilance database. In Vivo. 2024;38(3):1285\u201391. https:\/\/doi.org\/10.21873\/invivo.13567.","journal-title":"In Vivo"},{"issue":"3","key":"1914_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","volume":"115","author":"D Li","year":"2024","unstructured":"Li D, Wang H, Qin C, et al. Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Clin Pharmacol Ther. 2024;115(3):535\u201344. https:\/\/doi.org\/10.1002\/cpt.3139.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1914_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1080\/00365520600761676","volume":"41","author":"IA Eland","year":"2006","unstructured":"Eland IA, Sundstrom A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol. 2006;41(12):1484\u201390. https:\/\/doi.org\/10.1080\/00365520600761676.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"1914_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41390-021-01796-w","volume":"92","author":"CB Chen","year":"2022","unstructured":"Chen CB, Chang HH, Chou SW, et al. Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensity. Pediatr Res. 2022;92(2):459\u201365. https:\/\/doi.org\/10.1038\/s41390-021-01796-w.","journal-title":"Pediatr Res"},{"issue":"5","key":"1914_CR23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60188","volume":"16","author":"Y Kureyama","year":"2024","unstructured":"Kureyama Y, Hanaoka Y, Tomita D, et al. Pancreatitis after treatment with encorafenib, binimetinib, and cetuximab for BRAF V600E mutation-positive colorectal cancer. Cureus. 2024;16(5): e60188. https:\/\/doi.org\/10.7759\/cureus.60188.","journal-title":"Cureus"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"1231320","DOI":"10.3389\/fphar.2023.1231320","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Mao W, Liu D, et al. Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1231320. https:\/\/doi.org\/10.3389\/fphar.2023.1231320.","journal-title":"Front Pharmacol"},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","volume":"15","author":"KA Alenzi","year":"2024","unstructured":"Alenzi KA, Alsuhaibani D, Batarfi B, et al. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024;15:1364110. https:\/\/doi.org\/10.3389\/fphar.2024.1364110.","journal-title":"Front Pharmacol"},{"key":"1914_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.977582","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Mao W, Li X, et al. Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database. Front Pharmacol. 2022;13: 977582. https:\/\/doi.org\/10.3389\/fphar.2022.977582.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1914_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.clinthera.2024.04.005","volume":"46","author":"H Yang","year":"2024","unstructured":"Yang H, An Z, Zhao Y, et al. Tacrolimus related acute pancreatitis: an observational, retrospective. Pharmacovigil Study Clin Ther. 2024;46(7):524\u20138. https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.005.","journal-title":"Pharmacovigil Study Clin Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01914-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:31:14Z","timestamp":1757665874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01914-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}